Franklin Genomic Advancements ETF (HELX)

Assets	$9.99M
Expense Ratio	0.50%
PE Ratio	19.07
Shares Out	350,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Ratio	n/a
1-Year Return	+7.03%

Volume	524
Open	28.86
Previous Close	28.80
Day's Range	28.86 - 29.22
52-Week Low	27.54
52-Week High	33.98
Beta	1.08
Holdings	66
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

44.37% of assets

Name	Symbol	Weight
Vertex Pharmaceuticals Incorporated	VRTX	6.11%
Natera, Inc.	NTRA	5.68%
Krystal Biotech, Inc.	KRYS	4.76%
Samsung Biologics Co.,Ltd.	207940	4.53%
Eli Lilly and Company	LLY	4.44%
Regeneron Pharmaceuticals, Inc.	REGN	4.30%
Danaher Corporation	DHR	4.14%
Thermo Fisher Scientific Inc.	TMO	4.01%
Medpace Holdings, Inc.	MEDP	3.76%
United Therapeutics Corporation	UTHR	2.66%